Oceanía · Actualidad · Herald Sun

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

Publicado por Herald Sun · Australia hace 11 h

Alterity Therapeutics has presented additional analyses of its Phase 2 trial showing the 50mg twice-daily dose of its lead drug candidate ATH434 slowed functional ...

Leer el artículo completo en Herald Sun Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.heraldsun.com.au)

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

También te puede interesar

Behind the scenes at Perth’s most controversial expo

Judith Lucy announces breast cancer diagnosis: ‘I’m in shock, but I’m OK’

The Lowe Files official trailer

The Lowe Files official trailer

EVs outsell petrol cars again and account for nearly one in four new car sales – led by BYD, Tesla and Geely

The media’s deficit fetish harms the ‘people doing it tough’ it claims to represent

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

Compartir

También te puede interesar

Behind the scenes at Perth’s most controversial expo

Judith Lucy announces breast cancer diagnosis: ‘I’m in shock, but I’m OK’

The Lowe Files official trailer

The Lowe Files official trailer

EVs outsell petrol cars again and account for nearly one in four new car sales – led by BYD, Tesla and Geely

The media’s deficit fetish harms the ‘people doing it tough’ it claims to represent